Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/1/2025 | $3.70 | Neutral → Buy | Ladenburg Thalmann |
| 8/1/2025 | Buy → Neutral | H.C. Wainwright | |
| 3/12/2025 | $11.00 → $5.50 | Outperform → Sector Perform | RBC Capital Mkts |
| 3/12/2025 | Buy → Neutral | Ladenburg Thalmann | |
| 10/16/2023 | $13.00 | Outperform | RBC Capital Mkts |
| 1/6/2023 | $10.00 → $18.00 | Neutral → Overweight | Piper Sandler |
| 2/28/2022 | $15.50 → $10.00 | Buy | B. Riley Securities |
| 2/25/2022 | $22.00 → $20.00 | Buy | HC Wainwright & Co. |
ENGLEWOOD, Colo., Aug. 18, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the arrival of newly appointed CEO, Steven Dyson, and the appointment of several new leaders at the Company. On June 30, 2025, the Company announced the Board's appointment of Steven Dyson as the incoming CEO. Since that time, Mr. Dyson and Thomas Sandgaard, the Chairman of the Board, have been actively working wi
ENGLEWOOD, Colo., July 31, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the second quarter ended June 30, 2025. Management Commentary "In the second quarter of 2025, we completed two transformational events. First, we appointed Steven Dyson as our new CEO. Steven brings over 25 years of experience in the medical technology sector, primarily thro
ENGLEWOOD, Colo., July 22, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, July 31, 2025 at 4:15 PM Eastern Time to discuss its financial results for the second quarter ended June 30, 2025. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: Thursday
8-K - ZYNEX INC (0000846475) (Filer)
10-Q - ZYNEX INC (0000846475) (Filer)
8-K - ZYNEX INC (0000846475) (Filer)
3 - ZYNEX INC (0000846475) (Issuer)
4 - ZYNEX INC (0000846475) (Issuer)
4 - ZYNEX INC (0000846475) (Issuer)
4 - ZYNEX INC (0000846475) (Issuer)
Ladenburg Thalmann upgraded Zynex from Neutral to Buy and set a new price target of $3.70
H.C. Wainwright downgraded Zynex from Buy to Neutral
RBC Capital Mkts downgraded Zynex from Outperform to Sector Perform and set a new price target of $5.50 from $11.00 previously
ENGLEWOOD, Colo., Aug. 18, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the arrival of newly appointed CEO, Steven Dyson, and the appointment of several new leaders at the Company. On June 30, 2025, the Company announced the Board's appointment of Steven Dyson as the incoming CEO. Since that time, Mr. Dyson and Thomas Sandgaard, the Chairman of the Board, have been actively working wi
ENGLEWOOD, Colo., June 30, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the appointment of Steven Dyson as Chief Executive Officer. His employment will begin on August 18, 2025. Thomas Sandgaard, Founder of Zynex and Chairman of the Board since the company's inception in 1996, will remain actively involved as Chairman and Chair of the Board's Technology Committee. Steven brings over 25 years of experience in the me
ENGLEWOOD, Colo., Dec. 3, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced its membership in the Collaborative Community of the independently led Open Oximetry Project as an industry member. The Open Oximetry Project, an initiative led by the University of California, San Francisco's Center for Health Equity in Surgery and Anesthesia, is dedicated to i
SC 13D/A - ZYNEX INC (0000846475) (Subject)
ENGLEWOOD, Colo., July 31, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the second quarter ended June 30, 2025. Management Commentary "In the second quarter of 2025, we completed two transformational events. First, we appointed Steven Dyson as our new CEO. Steven brings over 25 years of experience in the medical technology sector, primarily thro
ENGLEWOOD, Colo., July 22, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, July 31, 2025 at 4:15 PM Eastern Time to discuss its financial results for the second quarter ended June 30, 2025. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: Thursday
ENGLEWOOD, Colo., April 29, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the first quarter ended March 31, 2025. Management Commentary "In the first quarter of 2025, we continued to see steady orders for our pain management and private-labeled rehabilitation products. Total orders decreased 3% year-over-year, but our sales force headcount was ap